Hannah Scott

I work in at the Nuffield Department of Clinical Medicine (Research Building), in the Target Discovery Institute within the Medical and Life Science Division at the Mass Spectrometry and Life Sciences group (Kessler lab).

My research focusses on metabolomics, lipidomics and ubiquitin biology. My research projects are based on 1. deubiquitylating enzymes (DUBs) and cancer of which ubiquitin specific protease 18 (USP18) is of particular interest, especially its potential role in lipid metabolism, inflammation and immunity. 2. women’s health such as polycystic ovarian syndrome and uterine fibroids, targeting the role of USP19 and probing the function of steroid sex hormones and other lipids in these diseases and 3.) providing lipidomics and metabolomics analysis to collaborative partners as part of the Metabolomics Small Research Facility.

_{https://www.tdi.ox.ac.uk/research/research/tdi-mass-spectrometry-laboratory/mass-spectrometry/techniques-and-expertise/metabolomics-lipidomics}

USP28 deletion and small molecule inhibition destabilises c-MYC and elicits regression of squamous cell lung carcinoma

E. Josue Ruiz, Adan Pinto-Fernandez, Andrew P. Turnbull, Linxiang Lan , Thomas M. Charlton, Hannah Claire Scott, Andreas Damianou, George Vere, Eva M. Riising, Clive Da Costa, Wojciech W. Krajewski, David Guerin, Jeffrey Kearns, Stephanos Ioannidis, Marie Katz, Crystal McKinnon, Jonathan C. O'Connell, Natalia Moncaut, Ian Rosewell, Emma Nye, Neil Jones, Claire Heride, Malte Gersch, Min Wu, Christopher J. Dinsmore, Tim R. Hammonds, Sunkyu Kim, David Komander, Sylvie Urbé, Michael J. Clague, Benedikt M. Kessler and Axel Behrens.

eLife 2021;10:e71596

Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.